Crispr Therapeutics Stock News

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.

It's climbed 15% since the start of the year.

CRISPR Therapeutics <> and ViaCyte said the first patient was dosed in a phase 1 trial of their gene-edited cell replacement therapy VCTX210 to treat type 1 diabetes (T1D)

Despite recent issues, Vertex Pharmaceuticals' long-term thesis is intact.

Shares of Crispr Therapeutics gained 3.1% in premarket trading on Wednesday after the company said the first patient had been dosed in a Phase 1 clinical trial evaluating the experimental type 1 diabetes treatment it developed with the privately held ViaCyte Inc. The investigational treatment uses ViaCyte''s stem cell-derived therapy in combination with Crispr''s gene-editing technology to generate pancreatic cells. Crispr''s stock has tumbled 61.0% over the past year, while the S&P 500 has gained 20.4%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

ZUG, Switzerland, and CAMBRIDGE, Mass., and SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today announced the first patient has been dosed in the Phase 1 clinical trial of VCTX210 for the treatment of type 1 diabetes (T1D). VCTX210 is an investigational, allogeneic, gene-edited, stem cell-derived product developed in collaboration by applying CRISPR Therapeutics'' gene-editing technology to ViaCyte''s proprietary stem cell capabilities for the generation of pancreatic cells designed to evade recognition by the immune system. This immune-evasive cell replacement therapy is designed to enable patients to produce their own insulin. "We are excited to work with CRISPR Therapeutics and ViaCyte to carry out this historic, first-in-human transplant of gene-edited, stem cell-derived pancreatic cells for the treatment of diabetes designed to eliminate the need for immune suppression," said James Shapiro, M.D., Ph.D., Canada Research Chair, Director of the Islet Transplant Program at the University of Alberta, Canada, and a clinical investigator in the trial. "If this approach is successful, it will be a transformative treatment for patients with all insulin-requiring forms of diabetes." The Phase 1 clinical trial of VCTX210 will assess its safety, tolerability, and immune evasion in patients with T1D.

Shares of Crispr Therapeutics CRSP, +2.79% gained 3.1% in premarket trading on Wednesday after the company said the first patient had been dosed in a Phase 1 clinical trial evaluating the experimental

Its plan to diversify into new therapy areas is continuing to take shape.

From industrial giants to tech stars to a big biotech, these stocks look like great picks to buy now.

They're risky. But they could also be huge winners.

They're risky. But they could also be huge winners.

And a look at market news including Netflix shares falling more than 20% as increasing competition cuts into subscriber growth.

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $59, marking a +0.41% move from the previous day.

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $59, marking a +0.41% move from the previous day.

One of these biotech stocks could have more room to run than the other.